Latest Breaking News On - Carl spana - Page 1 : comparemela.com

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

Palatin Stock Drops As Co-Primary Sign, Secondary Sign Endpoints Not Met In PL9643 Phase 3 DED Trial

Palatin Technologies, Inc.'s (PTN) shares were losing more than 38 percent in pre-market activity on the NYSE after the biopharmaceutical company announced that co-primary sign endpoint and secondary sign endpoints in its PL9643 MELODY-1 pivotal Phase 3 clinical trial in dry eye disease did not achieve statistical significance.

Taming the Immune System When Rare Diseases Strike

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Palatin s Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED).